Table 1. Demographics and characteristics of the included studies.
| Study | Year | Study design | Patients (n) | Intervention | Dose (mg/d) | Mean age (years) | Men n (%) | LDL-C (mg/dL) at baseline | LDL-C (mg/dL) at follow-up | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|
| Nasu et al. | 2009 | Nonrandomized | 40 | Fluvastatin | 60 | 63±10 | 32(80) | 144.9±31.5 | 98.1±12.7 | 12 |
| 40 | Usual care | NA | ||||||||
| Hong et al. | 2009 | RCT | 50 | Simvastatin | 20 | 58±10 | 40(80) | 119±30 | 78±20 | 12 |
| 50 | Rosuvastatin | 10 | 59±9 | 37(74) | 116±28 | 64±21 | 12 | |||
| HEAVEN | 2012 | RCT | 47 | Statins | NA | 65.1±10.6 | 31(66) | 104.4±30.9 | 100.5±30.9 | 12 |
| 42 | Statins+ezetimibe | NA | ||||||||
| Eshtehardi et al. | 2012 | Nonrandomized | 20 | Atorvastatin | 80 | 54 | 13(65) | 120.7±8.8 | 70.7±8.3 | 6 |
| Shin et al. | 2012 | Nonrandomized | 24 | Simvastatin | 20 | 60.2 ± 8.2 | 16 (73) | 105.5±50.2 | 60.6±20.9 | 12 |
| 24 | Rosuvastatin | 10 | 61.6 ± 9.3 | 13 (56) | 94.4±30.6 | 53.4±21.4 | 12 | |||
| VENUS | 2012 | RCT | 19 | Atorvastatin | 10 | 65.05±9.99 | 14 (74) | 122.39±39.54 | 68.53±26.80 | 6 |
| 20 | Atorvastatin | 40 | 63.70±9.80 | 18 (90) | 112.35±27.14 | 52.12±12.63 | 6 | |||
| LAMIS | 2012 | Nonrandomized | 94 | Pitavastatin | 2 | 64.3±10.1 | 68 (72) | 118.9±29.7 | 85.9±20.8 | 8 |
| Hwang et al. | 2013 | Nonrandomized | 54 | Statins | NA | 59±10 | 38 (70) | 119.7±31.4 | 67.3±20.4 | 6 |
| VIRHISTAMI | 2013 | RCT | 44 | Rosuvastatin | 5 | 60.0±10.3 | 38(86.4) | 119.9±27.1 | 77.3±15.5 | 12 |
| 43 | Rosuvastatin | 40 | 62.0±9.9 | 35(81.4) | 119.9±38.7 | 61.9±27.1 | 12 | |||
| Puri et al. | 2014 | RCT | 71 | Rosuvastatin/Atorvastatin | 40/80 | 57.6±9.0 | 59(80.3) | 128.6±30.7 | 72.4±25.9 | 24 |
Abbreviations: RCT: randomized controlled trial; LDL-C: low-density lipoprotein cholesterol.